Recent News

• 03.04.2026 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 03.03.2026 - Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
• 02.03.2026 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 01.05.2026 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 11.04.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 10.28.2025 - Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-derived CAR T-cell Therapy

Recent Filings

• 02.26.2026 - EX-99.1 EX-99.1
• 02.26.2026 - 8-K Current report
• 02.26.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.09.2026 - 144 Report of proposed sale of securities
• 01.09.2026 - 144 Report of proposed sale of securities